Yazar "Yigenoglu, Tugce Nur" seçeneğine göre listele
Listeleniyor 1 - 2 / 2
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Brentuximab Vedotin Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma: Multi-Center Retrospective Study(Cig Media Group, Lp, 2021) Ozbalak, Murat; Akay, Olga Meltem; Pehlivan, Mustafa; Yildiz, Birol; Uzay, Ant; Yigenoglu, Tugce Nur; Elverdi, Tugrul[Abstract Not Available]Öğe Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey(Taylor & Francis Ltd, 2023) Bakirtas, Mehmet; Dal, Mehmet Sinan; Yigenoglu, Tugce Nur; Giden, Asli Odabasi; Serin, Istemi; Basci, Semih; Kalpakci, YasinA multicenter, retrospective, observational study was conducted to explore effectiveness and safety of ixazomib plus lenalidomide with dexamethasone (IRd) in relapsed/refractory multiple myeloma (RRMM) patients following at least >= two lines of therapy. Patients' treatment responses, overall response rate, progression-free survival rate, and adverse events were recorded. Mean age of 54 patients was 66.5 +/- 9.1 years. There were 20 patients (37.0%) with progression. Median progression-free survival was 13 months in patients who received a median of three therapy lines in a 7.5-month follow-up period. Overall response rate was 38.5%. Of 54 patients, 19 (40.4%) had at least one adverse event, and nine (19.1%) had an adverse event of at least grade 3 or more. Of 72 adverse events observed in 47 patients, 68% were grade 1 or 2. Treatment was not stopped in any patient due to adverse events. IRd combination therapy was effective and safe in heavily treated RRMM patients.
